MOLT-4 cell MOLT-4 细胞 NICR43 cell NICR43 细胞 1. Cell Resource Center of Peking Union Medical College provides experimental cell technology services for scientific research. The provided experimental cells and their offspring can not be used in human experiments and clinical diagnosis and treatment, and can not be used for commercial activities directly or indirectly. 2. Cell Resource Center of Peking Union Medical College is committed to doing its utmost to update experimental cell resources in a timely fashion. But limited to the technical conditions at the time, the center does not guarantee its accuracy. 3. The Center did not verify information cited from the literature, etc, for reference purposes only. 4. Users should observe the relevant laws and regulations at home and abroad when receiving, handling, preserving, discarding, transferring and using cells, taking into account the risks and liabilities that may exist and taking appropriate safety and handling measures to minimize hazards to health or the environment. 3111C0001CCC000043 84~89 Amelogenin:X,Y；CSF1PO:11,12,13；D13S317:12,13；D16S539:11,14；D18S51:13,17；D19S433:14,15；D21S11:28,29,30,31；D2S1338:23,24；D3S1358:14,16；D5S818:12；D7S820:8,10,11；D8S1179:9,14；FGA:22,23,25；TH01:6,8；TPOX:8；vWA:17,18 Base Medium+8%DMSO+20%FBS C5 Cell Culture Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences Class A Culture Method（-） Human Acute Lymphoblastic Leukemia Cells; MOLT-4 MOLT-4 MOLT-4 and MOLT-3 are derived from a 19-year-old male patient with relapse of acute lymphoblastic leukemia who received multi-drug combination chemotherapy. The MOLT-4 cell line is of T lymphocyte origin and has a G → A mutation at codon 248 of p53 gene, and does not express p53, immunoglobulin or Epstein-Barr virus; it can produce a high level of terminal deoxyribonucleotidyl-transferase; it can express CD1 (49%), CD2 (35%), CD3 A (26%) B (33%) C (34%), CD4 (55%), CD5 (72%), CD6 (22%), CD7 (77%). MOLT-4 cell Maintain the cell concentration between 4 � 105/ml ~ 2 � 106/ml; and replenish the fluid according to the cell concentration every 2 to 3 days. Molt-4-Species Identification-PUMC NICR43 RPMI 1640 (w/o Hepes) 10%FBS Zhenli Yang, Yuqin Liu, Tel:65286441, 69156455, Email:crcpumc@vip.163.com http://www.cellresource.cn/fdetail.aspx?id=43 http://www.cellresource.cn/pdf/20080108101040.pdf lymphoblast-like; round suspension growth 1. 协和细胞资源中心为科学研究提供实验细胞技术服务。所提供的实验细胞及其子代，不能用于人体实验和临床诊断、治疗，不能直接或间接用于商业行为。 2. 协和细胞资源中心承诺尽最大努力对实验细胞资源相关信息进行及时更新。但限于当时的技术条件，中心不保证其准确性。 3. 从文献等处引用的信息本中心未进行核实，仅供参考。 4. 使用者在接收、处理、保存、丢弃、转让及使用细胞的时候要遵守国内外有关的法律法规，充分考虑可能存在的风险和责任，采取适当的安全和处理措施尽量降低对健康或环境的危害 84~89 Amelogenin:X,Y；CSF1PO:11,12,13；D13S317:12,13；D16S539:11,14；D18S51:13,17；D19S433:14,15；D21S11:28,29,30,31；D2S1338:23,24；D3S1358:14,16；D5S818:12；D7S820:8,10,11；D8S1179:9,14；FGA:22,23,25；TH01:6,8；TPOX:8；vWA:17,18 A类 C5 MOLT-4 细胞 MOLT-4与MOLT-3来源于一名19岁的男性急性淋巴细胞性白血病的复发患者，该患者前期接受过多种药物联合化疗。MOLT-4细胞系为T淋巴细胞起源，p53基因的第248位密码子有一个G→A突变，不表达p53，不表达免疫球蛋白或EB病毒；可产生高水平的末端脱氧核糖转移酶；表达CD1 (49%), CD2 (35%), CD3 A (26%) B(33%) C (34%), CD4 (55%), CD5 (72%), CD6 (22%), CD7 (77%)。 Molt-4-物种鉴定-PUMC RPMI 1640 (w/o Hepes) 10%FBS http://www.cellresource.cn/pdf/20080108101040.pdf 中国医学科学院基础医学研究所基础医学细胞中心 人急性淋巴母细胞性白血病细胞；MOLT-4 培养法（-） 基础培养基+8%DMSO+20%FBS 悬浮生长 杨振丽，刘玉琴，Tel:65286441，69156455；Email:crcpumc@vip.163.com 淋巴母细胞样；圆形 维持细胞浓度在4×105/ml~2×106/ml；根据细胞浓度每2~3天补液1次。